4.7 Article

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Prognostic and predictive value ofPD-L2DNA methylation and mRNA expression in melanoma

Friederike Hoffmann et al.

CLINICAL EPIGENETICS (2020)

Article Medicine, General & Internal

Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma

Anne Froehlich et al.

EBIOMEDICINE (2020)

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Medicine, Research & Experimental

CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients

Diane Goltz et al.

JCI INSIGHT (2018)

Article Oncology

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

Tavi Nathanson et al.

CANCER IMMUNOLOGY RESEARCH (2017)

Article Multidisciplinary Sciences

Effector CD8 T cells dedifferentiate into long-lived memory cells

Ben Youngblood et al.

NATURE (2017)

Review Oncology

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Mizuki Nishino et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Article Biochemistry & Molecular Biology

De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation

Hazem E. Ghoneim et al.

Article Medicine, Research & Experimental

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma

Adil I. Daud et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

Review Genetics & Heredity

Targeting the cancer epigenome for therapy

Peter A. Jones et al.

NATURE REVIEWS GENETICS (2016)

Article Multidisciplinary Sciences

The epigenetic landscape of T cell exhaustion

Debattama R. Sen et al.

SCIENCE (2016)

Article Multidisciplinary Sciences

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Kristen E. Pauken et al.

SCIENCE (2016)

Article Medicine, General & Internal

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Multidisciplinary Sciences

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh et al.

NATURE (2014)

Article Medicine, General & Internal

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Review Immunology

CTLA-4 trafficking and surface expression

Elke Valk et al.

TRENDS IN IMMUNOLOGY (2008)